###begin article-title 0
###xml 14 17 14 17 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A </sub>
###xml 25 27 25 27 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6 </sub>
###xml 92 100 <span type="species:ncbi:9606">patients</span>
Serotonin 5-HT2A and 5-HT6 receptors in the prefrontal cortex of Alzheimer and normal aging patients
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 195 198 195 198 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A </sub>
###xml 206 208 206 208 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6 </sub>
###xml 291 299 <span type="species:ncbi:9606">patients</span>
It has been hypothesized that alterations of the serotonergic system contribute to neuropsychiatric symptoms in Alzheimer disease (AD). Cellular expressions of the two serotonergic receptors 5-HT2A and 5-HT6 have therefore been determined by immunohistochemistry in the prefrontal cortex of patients with AD (n=6) and normal age-matched controls (n = 7).
###end p 3
###begin title 4
Results
###end title 4
###begin p 5
###xml 30 33 30 33 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A </sub>
###xml 329 331 329 331 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6 </sub>
###xml 525 527 525 527 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6 </sub>
###xml 16 24 <span type="species:ncbi:9606">patients</span>
###xml 311 319 <span type="species:ncbi:9606">patients</span>
###xml 553 561 <span type="species:ncbi:9606">patients</span>
In normal aging patients, 5-HT2A label was mainly observed in large pyramidal cells, but to a lesser extent also in small pyramidal cells and in stellate cells of cortical layers II-VI. In AD, a similar distribution was observed, but density of positive cells was significantly reduced by 33%. In aging control patients, the 5-HT6 receptor was expressed by pyramidal cells and occasional stellate cells, not only of layers II-V, but also of layer I, where a distinct label was observed in neurons and surrounding fibers. 5-HT6 receptor expression in AD patients had the same pattern, but was significantly decreased by 40%.
###end p 5
###begin title 6
Conclusion
###end title 6
###begin p 7
###xml 62 64 62 64 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A</sub>
###xml 79 81 79 81 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6 </sub>
Our results indicate that a decline in neurons expressing 5-HT2A, but also 5-HT6 receptors may play a role in the etiopathology of neuropsychiatric symptoms in AD.
###end p 7
###begin title 8
Background
###end title 8
###begin p 9
###xml 363 364 363 364 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 365 366 365 366 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 552 553 552 553 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 554 555 554 555 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 556 557 556 557 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 660 661 660 661 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 662 663 662 663 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 664 665 664 665 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 714 715 714 715 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 716 717 716 717 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 718 720 718 720 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 799 802 799 802 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1&#8211;7</sub>
###xml 889 891 889 891 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 903 906 903 906 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A </sub>
###xml 1018 1021 1018 1021 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A </sub>
###xml 1088 1090 1088 1090 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 1097 1100 1097 1100 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A </sub>
###xml 1164 1166 1164 1166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 1167 1169 1167 1169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 1345 1347 1345 1347 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 1348 1350 1348 1350 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 1365 1367 1365 1367 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 1382 1384 1382 1384 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 1435 1438 1435 1438 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A </sub>
###xml 1529 1531 1529 1531 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 1532 1534 1532 1534 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 1594 1596 1594 1596 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 1628 1631 1628 1631 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A </sub>
###xml 1772 1775 1772 1775 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A </sub>
###xml 1786 1788 1786 1788 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 1795 1798 1795 1798 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A </sub>
###xml 1852 1853 1852 1853 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 1854 1856 1854 1856 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 1915 1919 1915 1919 <italic xmlns:xlink="http://www.w3.org/1999/xlink">5-HT</italic>
###xml 1920 1922 1920 1922 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A </italic>
###xml 1919 1922 1919 1922 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2<italic>A </italic></sub>
###xml 1972 1974 1972 1974 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 1989 1991 1989 1991 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 2015 2017 2015 2017 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 2059 2061 2059 2061 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6 </sub>
###xml 2186 2188 2186 2188 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6 </sub>
###xml 2198 2200 2198 2200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 2201 2203 2201 2203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 2282 2284 2282 2284 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 2357 2359 2357 2359 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 2405 2408 2405 2408 <sup xmlns:xlink="http://www.w3.org/1999/xlink">125</sup>
###xml 2487 2489 2487 2489 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6 </sub>
###xml 2544 2545 2544 2545 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 2565 2569 2565 2569 <italic xmlns:xlink="http://www.w3.org/1999/xlink">5-HT</italic>
###xml 2569 2571 2569 2571 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6 </sub>
###xml 2668 2670 2668 2670 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 2693 2695 2693 2695 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 1279 1287 <span type="species:ncbi:9606">patients</span>
###xml 2456 2464 <span type="species:ncbi:9606">patients</span>
Alzheimer disease (AD), the most common cause of dementia in the elderly, is clinically characterized by progressive cognitive impairment associated with severe neuropsychiatric disturbances. These behavioral and psychological symptoms of dementia (BPSD) include hallucinations, delusions, aggressive behavior, overactivity, anxieties and affective disturbances [1,2]. Whereas the decline in cognitive functions can be largely related to cholinergic dysfunction arising from disruption of basal forebrain cholinergic pathways (cholinergic hypothesis) [1,3,4], impaired balance between several neurotransmitters has been implicated in the pathogenesis of BPSP [2,5-7], with serotonin (5-HT) playing a pivotal role [2,8-10]. The actions of 5-HT are mediated through seven major receptors classes, 5-HT1-7, comprising a total of 14 distinct mammalian 5-HT receptor subtypes (for review, see [11]). The 5-HT2A receptor has attracted most interest because of its possible participation in behavioral alterations in AD. 5-HT2A is localized in the cortex and caudate and is involved in anxiety [10]. 5-HT2A receptors mediate the psychotomimetic effects of hallucinogens [11-13], and alterations in binding characteristics to this receptor have been observed in the prefrontal cortex of patients suffering from psychiatric diseases, e.g. schizophrenia [14,15], depression [16] and suicide [17]. Electrophysiological evidence suggests that 5-HT2A receptors are involved in the 5-HT-induced increase in excitatory postsynaptic potentials [12,18] and play an important role in the working memory process [13]. There is indication that 5-HT2A also participates in the etiopathology of AD. Serotonin increases the secretion of amyloid precursor protein (APP) through activation of 5-HT2A receptors [19]. 5-HT2A receptor binding is decreased in AD (for review, see [9,10]), and polymorphic variations have been described for the 5-HT2A gene that may be risk factors for hallucinations [20], aggression [21] and major depression [22] in AD. Much less is known about the 5-HT6 receptor, the most recent 5-HT receptor to be identified. Many antidepressants and antipsychotics are antagonists of the 5-HT6 receptor [15,23]. It has been shown to influence acetylcholine release in the frontal cortex [24] and may play a role in cognition deficits and in some form of anxiety [23]. A recent autoradiographic study examining [125I]-SB-258585 binding in autopsy specimens of AD patients indicates lowered 5-HT6 receptor density in the frontal and temporal cortices [5]. Association of a 5-HT6 receptor gene polymorphic variant and late-onset AD has been observed in the Chinese population [25], but not in Germans [26].
###end p 9
###begin p 10
###xml 27 30 27 30 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A </sub>
###xml 93 94 93 94 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 95 96 95 96 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 97 98 97 98 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 99 101 99 101 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 241 244 241 244 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A </sub>
###xml 252 254 252 254 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6 </sub>
###xml 435 436 435 436 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 437 438 437 438 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 439 441 439 441 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 442 444 442 444 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 445 447 445 447 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 448 450 448 450 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 451 453 451 453 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 539 541 539 541 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 542 544 542 544 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 561 563 561 563 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 312 320 <span type="species:ncbi:9606">patients</span>
Surprisingly, although 5-HT2A and 5-HT6 receptor binding in AD has been studied extensively [2,5,9,10], there is no information on the expression of these receptors at the cellular level. We have therefore examined the expression of the 5-HT2A and 5-HT6 receptors in the brains of AD and of normal aging control patients by immunohistochemistry. Because the prefrontal cortex is of particular importance for the etiopathology of BPSD [1,8,12,14,16,27-31] and because neuropsychiatric symptoms in AD are associated with reduced metabolism [32,33] and perfusion [34] in Brodmann area 10, we have chosen this brain region for examination.
###end p 10
###begin title 11
Methods
###end title 11
###begin title 12
Tissue samples
###end title 12
###begin p 13
###xml 381 382 381 382 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 452 463 452 463 <italic xmlns:xlink="http://www.w3.org/1999/xlink">postmortem </italic>
###xml 566 574 <span type="species:ncbi:9606">patients</span>
The brains were obtained from a total of 13 autopsy cases with the consent of a close relative and with full approval by the ethical committees of Guangzhou hospital authorities and of the Chinese University of Hong Kong. Six of the specimens were from individuals with clinically and pathologically diagnosed senile dementia of the Alzheimer's type (mean age: 88 years, see table 1), seven specimens were from individuals, matched for age, gender and postmortem delay, who had no history of neurological diseases (normal control). Drug history was recorded for all patients, who had only received antibiotic treatment, but no psychopharmacological medication. Alzheimer Disease was clinically diagnosed according to the "National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association" (NINCDS-ADRA) criteria and the "Diagnostic and Statistical Manual of Mental Disorders", Fourth Edition, (DSM-IV-R) criteria.
###end p 13
###begin p 14
###xml 42 53 42 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink">postmortem </italic>
Whole brains were removed with an average postmortem delay of six hours, and tissue samples of the anterior prefrontal cortex (Brodmann's area 10) were dissected. Specimens were fixed overnight in 4% paraformaldehyde in phosphate-buffered saline (PBS; ph 7.4), dehydrated in graded ethanol, cleared with xylene and embedded in paraffin. 6-mum-thick serial sections were cut in the coronal plane, 90degrees perpendicular to the surface to avoid sectioning artifacts. Two sets of slides were obtained for each individual.
###end p 14
###begin title 15
Immunohistochemistry
###end title 15
###begin p 16
###xml 237 239 237 239 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 607 609 601 603 <sup xmlns:xlink="http://www.w3.org/1999/xlink">R </sup>
###xml 1158 1160 1152 1154 <sup xmlns:xlink="http://www.w3.org/1999/xlink">R </sup>
###xml 1303 1305 1297 1299 <sup xmlns:xlink="http://www.w3.org/1999/xlink">R </sup>
###xml 1544 1545 1538 1539 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1546 1547 1540 1541 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1893 1897 1887 1889 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
###xml 2064 2066 2056 2058 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 2067 2069 2059 2061 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 769 773 <span type="species:ncbi:9925">goat</span>
###xml 779 784 <span type="species:ncbi:9606">human</span>
###xml 878 882 <span type="species:ncbi:9925">goat</span>
###xml 888 893 <span type="species:ncbi:9606">human</span>
###xml 1138 1142 <span type="species:ncbi:9925">goat</span>
All steps were carried out at room temperature unless stated otherwise. Mounted sections were dewaxed, rehydrated and predigested with 0.1% trypsin (BDH Laboratory Supplies, Poole, U.K.) in 0.05M tris buffered saline containing 0.1% CaCl2 (pH 7.6; 37degreesC; 20 min) followed by two rinses (5 min) in 0.01M PBS for antigen retrieval. The endogenous peroxidase activity was blocked with 0.3% hydrogen peroxide in absolute methanol for 30 min, followed by another three rinses in PBS (5 min each). To suppress non-specific binding, sections were then incubated for 1h in 2 % normal blocking serum (VectastainR ABC Kit, Vector Laboratories, Burlingame, CA) in 0.3 % triton/PBS. Thereafter, sections were incubated overnight with the primary polyclonal antibodies: either goat anti-human serotonin 2A receptor (Santa Cruz sc-15073, Santa Cruz Biotechnology Inc., Sta. Cruz, CA) or goat anti-human serotonin 6 receptor (Santa Cruz sc-26668). The sections were then washed with three rinses of PBS containing 0.05 % Tween 20 (5 min each) and incubated with biotinylated secondary antibody in blocking solution (1:200) for 30 min (PK6105, anti-goat IgG, VectastainR ABC Kit, Vector Laboratories, Burlingame, CA). Sections were washed three times in PBS again (5 min) and incubated with ABC Reagent (VectastainR ABC Kit, Vector Laboratories, Burlingame, CA) for 30 min. The immunocytochemical staining signals were visualized by incubating the sections in 0.05% of the substrate 3'3'-diaminobenzidine tetrahydrochloride (DAB) in PBS containing 0.01% H2O2. All stainings included negative controls with omission of the primary antibody, which did not show any immunoreaction. The sections were washed with distilled water and then counterstained with 0.5% cresyl fast violet in 0.1M sodium acetate (pH 3.5, 5 min). They were differentiated with 95% ethanol, dehydrated, cleared and covered in Permount(R) (Fisher Scientific, Hampton, VA). Additional sections were stained with routine methods, including H&E, Nissl and Bielschowsky silver impregnation for tangle staging [35,36].
###end p 16
###begin p 17
###xml 134 136 134 136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 615 617 606 608 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 502 508 <span type="species:ncbi:9986">rabbit</span>
###xml 802 810 <span type="species:ncbi:9606">patients</span>
All cases underwent a standardized post-mortem neuropathological assessment of AD using established criteria including Braak staging [35]. Four brain regions were examined: prefrontal (area 10), occipital (area 17), entorhinal (area 28) and hippocampal cortices. Diagnosis was confirmed by the characteristic presence of amyloid plaques, neurofibrillary tangles (NFT) and neuronal degeneration. In addition, the presence of beta-amyloid in the plaques was ascertained by immunohistochemistry using the rabbit polyclonal Anti-Amyloid Peptide beta, Cleavage site 42 (Abeta42), antibody (A1976, Sigma, St. Louis, MU) [37]. All AD cases had neocortical NFT with involvement of both isocortical association areas and additional involvement of primary cortical (area 17) areas (Braak stage V-VI). In control patients, deposition of NFT was negligible in the entorhinal cortex and absent in the hippocampus as well as the neocortex (Braak stage = I). To exclude Dementia with Lewy bodies, all brain specimens were scrutinized for Lewy bodies, and only cases devoid of Lewy bodies were included in the study.
###end p 17
###begin title 18
Statistics
###end title 18
###begin p 19
###xml 156 158 156 158 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A</sub>
###xml 168 169 168 169 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6</sub>
###xml 232 234 231 233 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 393 395 392 394 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 471 474 467 470 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A </sub>
###xml 554 557 550 553 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A </sub>
###xml 263 271 <span type="species:ncbi:9606">patients</span>
###xml 383 391 <span type="species:ncbi:9606">patients</span>
###xml 522 530 <span type="species:ncbi:9606">patients</span>
For qualitative and quantitative evaluation, sections were observed under a photomicroscope (Axioplan 2 Photomicroscope, Zeiss, Germany). The number of 5-HT2A- and 5-HT6-immunoreactive cells was counted in 30 random selected 700 mum2 fields of normal aged and AD patients. 4-5 sections per individual were evaluated, sparing areas containing amyloid plaques. It has been shown in AD patients [38] that astrocytes in and around Abeta plaques are strongly positive for 5-HT2A receptor protein, whereas astrocytes in control patients do not display any 5-HT2A immunoreaction. Amyloid plaques were therefore excluded from the quantitative assessment, because the aim of our study was to count neurons expressing 5-HT receptors. Measurements were expressed as means +/- SEM. For statistical comparison, the values were subjected to a one-way analysis of variance (ANOVA), demonstrating that the four data groups exhibited equal variance, but were not distributed normally. We have then applied the One Way non-parametric ANOVA (Kruskal-Wallis test) and the Mann Whitney Rank sum test, yielding the same results. A p value below 0.05 was considered significant.
###end p 19
###begin title 20
Results
###end title 20
###begin p 21
###xml 55 58 55 58 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A </sub>
###xml 321 326 321 326 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1a, c</xref>
###xml 656 659 656 659 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A </sub>
###xml 725 728 725 728 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A </sub>
###xml 830 833 830 833 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A </sub>
###xml 1029 1034 1029 1034 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1b, d</xref>
###xml 1071 1074 1071 1074 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A </sub>
###xml 1192 1193 1192 1193 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 1414 1417 1414 1417 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A </sub>
###xml 41 49 <span type="species:ncbi:9606">patients</span>
###xml 784 792 <span type="species:ncbi:9606">patients</span>
###xml 1177 1185 <span type="species:ncbi:9606">patients</span>
###xml 1224 1232 <span type="species:ncbi:9606">patients</span>
In the prefrontal cortex of normal aging patients, 5-HT2A receptor immunoreaction was observed in cortical layers II-VI. Large pyramidal neurons of layer V constituted the majority of immunoreactive cells, characterized by a strongly labeled cytoplasm and a moderately stained proximal part of the apical dendrite (Figs. 1a, c). In addition, smaller pyramidal cells and scattered stellate-shaped cells in the other layers were immunoreactive. Stellate cells had a strongly stained cytoplasm and labeled thin processes radiating to the side of the ovoid cell bodies and most likely represented interneurons. A few multipolar cells in layer VI were also 5-HT2A receptor positive. In the underlying white matter, occasional 5-HT2A receptor immunoreactive fiber bundles were observed. AD patients showed a similar distribution of 5-HT2A receptor label in the prefrontal cortex, i.e. staining in the cell bodies and apical dendrites of large pyramidal cells and in the soma and tender processes of a few scattered interneurons (Figs. 1b, d). However, numerical density of 5-HT2A receptor immunoreactive cells was significantly (p=0.001) decreased by 33% in the frontal cortex of AD patients (Fig. 2), as compared to normal aging patients. Reduction affected both pyramidal cells and cells of stellate morphology. In addition, labeled cells were also seen within and close to amyloid plaques. An association between 5-HT2A receptors and NFT was not observed.
###end p 21
###begin p 22
###xml 20 22 20 22 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6 </sub>
###xml 140 143 140 143 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A </sub>
###xml 168 171 168 171 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A </sub>
###xml 402 407 402 407 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3a, c</xref>
###xml 427 429 427 429 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6 </sub>
###xml 648 650 648 650 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3d</xref>
###xml 681 683 681 683 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6 </sub>
###xml 849 851 849 851 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6 </sub>
###xml 919 922 919 922 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A </sub>
###xml 1007 1009 1007 1009 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6 </sub>
###xml 1068 1073 1068 1073 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3b, e</xref>
###xml 1105 1107 1105 1107 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6 </sub>
###xml 1223 1224 1223 1224 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 1327 1329 1327 1329 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6 </sub>
###xml 87 95 <span type="species:ncbi:9606">patients</span>
###xml 993 1001 <span type="species:ncbi:9606">patients</span>
###xml 1208 1216 <span type="species:ncbi:9606">patients</span>
Distribution of 5-HT6 receptor immunoreaction in the prefrontal cortex of normal aging patients was slightly different from that of the 5-HT2A receptor. As for the 5-HT2A receptor, the most prominent label was observed in the cell bodies and the proximal apical dendrites of large pyramidal neurons, and occasionally, the soma and fine processes of scattered stellate cells were stained as well (Figs. 3a, c). In addition, 5-HT6 receptor immunoreaction was also detected in neurons of the molecular layer (layer I). These cells had a bipolar strongly labeled cell body and numerous immunoreactive processes radiating into the molecular layer (Fig. 3d). In contrast, hardly any 5-HT6 receptor immunoreactive cells were observed in layer VI. Occasional immunoreactive fiber bundles were seen in the underlying white matter. In summary, density of 5-HT6 receptor positive neurons was significantly higher than that of 5-HT2A receptor immunoreactive cells (p=0.05). In the prefrontal cortex of AD patients, 5-HT6 receptor label showed the same overall distribution (Figs. 3b, e), but numerical density of 5-HT6 receptor immunoreactive cells was again significantly (p=0.001) reduced, as compared to normal aging patients (Fig. 2). Both pyramidal and stellate cells were decreased by about 40%. There was no association between 5-HT6 receptors and NFT.
###end p 22
###begin title 23
Discussion
###end title 23
###begin p 24
###xml 125 128 125 128 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A </sub>
###xml 136 137 136 137 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6</sub>
###xml 283 286 283 286 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A </sub>
###xml 456 458 456 458 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 471 473 471 473 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 474 476 474 476 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 491 493 491 493 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 494 496 494 496 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 606 609 606 609 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A </sub>
###xml 773 776 773 776 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A </sub>
###xml 855 856 855 856 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 890 892 890 892 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A</sub>
###xml 952 954 952 954 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6 </sub>
###xml 995 997 995 997 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6 </sub>
###xml 1136 1137 1136 1137 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 1138 1140 1138 1140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 1230 1232 1230 1232 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6 </sub>
###xml 1372 1374 1372 1374 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6 </sub>
###xml 1421 1423 1421 1423 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6 </sub>
###xml 1598 1600 1598 1600 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6 </sub>
###xml 1694 1696 1694 1696 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 1799 1801 1799 1801 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 170 178 <span type="species:ncbi:9606">patients</span>
###xml 261 269 <span type="species:ncbi:9606">patients</span>
###xml 448 454 <span type="species:ncbi:9606">humans</span>
###xml 667 675 <span type="species:ncbi:9606">patients</span>
###xml 1122 1127 <span type="species:ncbi:9606">human</span>
###xml 1573 1576 <span type="species:ncbi:10116">rat</span>
The present study has been undertaken in order to determine changes in cellular distribution of two serotonin receptors, 5-HT2A and 5-HT6, in the prefrontal cortex of AD patients as compared to normal age-matched individuals. Our observation in aging (control) patients, showing 5-HT2A immunoreactivity in the cell bodies and the apical dendrites of pyramidal cells as well as in stellate-shaped cells, is consistent with previous studies in young humans [17], primates [18,39] and rodents [40,41]. However, we have detected relatively few labeled cells, and we are currently testing if the paucity in 5-HT2A receptors is attributable to the very advanced age of our patients or to the technique employed. A considerable age-related reduction in the number of cortical 5-HT2A binding sites in the frontal lobe has been described by numerous authors (see [9] for review). In contrast to 5-HT2A, relatively little is known on the distribution of the 5-HT6 receptor in the mammalian neocortex. 5-HT6 receptor binding sites have been detected by receptor autoradiography in the gray matter of the prefrontal cortex of healthy human adults [5,42], but there are no studies on the cellular level. We have been able to show that the 5-HT6 receptor is expressed both by pyramidal cells and by stellate-shaped cells located in cortical layers I-V. We have observed very little 5-HT6 immunoreaction in layer VI, but a distinct 5-HT6 label in layer I, with staining detected not only in a dense network of fibers, but also in neurons. This is somewhat at variance with a study on the rat neocortex, where 5-HT6 receptor mRNA has been detected by in-situ hybridization in layers II-VI, but not in layer I [43]. This discrepancy is, however, not surprising, given the marked inter-species differences described [44].
###end p 24
###begin p 25
###xml 69 72 69 72 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A </sub>
###xml 163 166 163 166 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A </sub>
###xml 220 222 220 222 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3 </sup>
###xml 238 240 238 240 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 241 243 241 243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
###xml 249 251 249 251 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3 </sup>
###xml 266 268 266 268 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B48">48</xref>
###xml 273 284 273 284 <italic xmlns:xlink="http://www.w3.org/1999/xlink">postmortem </italic>
###xml 359 361 359 361 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B49">49</xref>
###xml 405 407 405 407 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3 </sup>
###xml 431 433 431 433 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
###xml 592 595 592 595 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A </sub>
###xml 664 666 664 666 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B51">51</xref>
###xml 734 737 734 737 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A </sub>
###xml 906 908 906 908 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6 </sub>
###xml 1023 1025 1023 1025 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6 </sub>
###xml 1076 1077 1076 1077 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 1141 1144 1141 1144 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A </sub>
###xml 1152 1154 1152 1154 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6 </sub>
###xml 1235 1236 1235 1236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 1566 1567 1566 1567 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 1568 1570 1568 1570 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 1571 1573 1571 1573 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B52">52</xref>
###xml 1764 1766 1764 1766 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B53">53</xref>
###xml 1767 1769 1767 1769 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B54">54</xref>
###xml 1911 1913 1911 1913 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B55">55</xref>
###xml 1978 1981 1978 1981 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A </sub>
###xml 1989 1991 1989 1991 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6 </sub>
###xml 2124 2125 2124 2125 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 2126 2128 2126 2128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B56">56</xref>
###xml 322 330 <span type="species:ncbi:9606">patients</span>
###xml 570 578 <span type="species:ncbi:9606">patients</span>
###xml 1066 1074 <span type="species:ncbi:9606">patients</span>
###xml 1556 1564 <span type="species:ncbi:9606">patients</span>
To our knowledge, this is the first immunohistochemical study of 5-HT2A receptor expression in AD. The reduction observed corroborates the results of previous 5-HT2A receptor binding studies showing decreased binding of 3 [H] ketanserin [45-47] and 3 [H] spiperone [48] in postmortem specimens of the frontal cortex of AD patients and in PET imaging studies [49]. Contrasting reports describing unaltered 3 [H] ketanserin binding [50], which are at variance with our results, may be attributable to recent psychotropic medication, which had not been administered to our patients. Reduced 5-HT2A receptor binding in AD has been explained by a loss of interneurons [51]. In contrast, our immunohistochemical data indicate that both 5-HT2A immunoreactive pyramidal and stellate-shaped cells, i.e. interneurons, are affected in AD. Moreover, we have demonstrated that the density of neurons expressing the 5-HT6 receptor is reduced to a similar extent, corroborating autoradiographic studies revealing decreased binding to 5-HT6 receptors in the prefrontal cortex of AD patients [5]. Our observation of reduced density of neurons expressing 5-HT2A and 5-HT6 receptors, which is not accompanied by similar alterations in GABAergic markers [6], points at a selective vulnerability of neurons receiving serotonergic input. This decrease is associated with several other abnormalities of the serotonergic system in AD. A marked depletion in 5-HT and its metabolite 5-Hydroxyindole Acetic Acid (5-HIAA) has been described in the frontal and temporal cortices of AD patients [2,28,52], which is most likely attributable to a reduction in serotonergic projection fibers. The underlying cause appears to be a significant loss of neurons in the dorsal and median raphe nuclei [53,54], which are the source of serotonergic nerve terminals and which, in addition, are a preferential site for neurofibrillary tangle formation [55]. It is very likely that the decrease in neurons expressing 5-HT2A and 5-HT6 receptors is related to this loss of serotonergic fibers. However, it may either reflect a process of primary cortical degeneration [4,56] leading to presynaptic disturbance of the serotonergic system, or be secondary to the decrease in serotonergic afferents.
###end p 25
###begin p 26
###xml 159 162 159 162 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A </sub>
###xml 229 231 229 231 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B57">57</xref>
###xml 270 280 270 280 <italic xmlns:xlink="http://www.w3.org/1999/xlink">antemortem</italic>
###xml 286 289 286 289 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A </sub>
###xml 413 415 413 415 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
###xml 456 458 456 458 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6 </sub>
###xml 564 565 564 565 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 779 781 779 781 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B52">52</xref>
###xml 874 875 874 875 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 194 202 <span type="species:ncbi:9606">patients</span>
###xml 351 359 <span type="species:ncbi:9606">patients</span>
###xml 499 507 <span type="species:ncbi:9606">patients</span>
###xml 666 674 <span type="species:ncbi:9606">patients</span>
###xml 746 754 <span type="species:ncbi:9606">patients</span>
Several lines of evidence indicate that serotonergic dysfunction in AD has important functional consequences. In a study using retrospective data, loss in 5-HT2A binding has been confined to AD patients with aggressive symptoms [57]. When cognitive function is assessed antemortem, 5-HT2A receptors are lost in the frontal and temporal cortex only in patients with severe, but not with mild to moderate dementia [47]. The decrease in the expression of 5-HT6 receptors in the prefrontal cortex of AD patients can be correlated to the extent of aggressive behavior [5]. The number of 5-HT uptake sites is significantly reduced in the frontal and temporal cortex of AD patients with persistent depression, anxiety and overactivity, compared with AD patients without these symptoms [52], and 5-HT levels in the prefrontal cortex (Brodmann 10) of AD correlate with overactivity [2].
###end p 26
###begin title 27
Conclusion
###end title 27
###begin p 28
###xml 55 58 55 58 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A </sub>
###xml 66 68 66 68 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6 </sub>
###xml 264 266 264 266 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A</sub>
###xml 285 287 285 287 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6 </sub>
###xml 362 365 362 365 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A </sub>
###xml 373 375 373 375 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6 </sub>
###xml 28 36 <span type="species:ncbi:9606">patients</span>
###xml 400 408 <span type="species:ncbi:9606">patients</span>
Our results of normal aging patients, showing that 5-HT2A and 5-HT6 receptors are expressed by both pyramidal cells and stellate-shaped neurons, indicate that serotonergic fibers exert their influence upon these two neocortical cell types not only through the 5-HT2A, but also the 5-HT6 receptor. The significant 33-40% reduction in cells immunoreactive for 5-HT2A and 5-HT6 receptors observed in AD patients, affecting both large pyramidal cells and interneurons, points at a severely compromised serotonergic system in AD, involving not only serotonergic projection fibers, but also their corresponding receptors. This decline in receptors most likely contributes to the development of neuropsychiatric symptoms in AD.
###end p 28
###begin title 29
Authors' contributions
###end title 29
###begin p 30
###xml 0 18 0 18 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Dietrich E. Lorke </bold>
###xml 107 115 107 115 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Gang Lu </bold>
###xml 173 182 173 182 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Eric Cho </bold>
###xml 235 248 235 248 <bold xmlns:xlink="http://www.w3.org/1999/xlink">David T. Yew </bold>
Dietrich E. Lorke performed the evaluation of the slides, interpreted the results and wrote the manuscript.Gang Lu performed immunohistochemistry and documented the results.Eric Cho performed the quantitative and statistical analyses. David T. Yew conceived and planned the study, performed the neuropathological examination and evaluated the slides.
###end p 30
###begin title 31
Abbreviations
###end title 31
###begin p 32
AD: Alzheimer disease
###end p 32
###begin p 33
BPSD: behavioral and psychological symptoms of dementia
###end p 33
###begin p 34
5-HT: serotonin
###end p 34
###begin p 35
###xml 4 6 4 6 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A</sub>
5-HT2A: serotonergic receptor 2A
###end p 35
###begin p 36
###xml 4 5 4 5 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6</sub>
5-HT6: serotonergic receptor 6
###end p 36
###begin p 37
NFT: neurofibrillary tangles
###end p 37
###begin p 38
PBS: phosphate-buffered saline
###end p 38
###begin p 39
SEM: standard error of the mean
###end p 39
###begin title 40
Acknowledgements
###end title 40
###begin p 41
The authors wish to thank Samuel Wong for skilful assistance in preparing the photographs and Stephanie Yeung for typing the manuscript.
###end p 41
###begin article-title 42
The cholinergic hypothesis of neuropsychiatric symptoms in Alzheimer's disease
###end article-title 42
###begin article-title 43
Cholinergic-serotonergic imbalance contributes to cognitive and behavioral symptoms in Alzheimer's disease
###end article-title 43
###begin article-title 44
Cholinergic function and Alzheimer's disease
###end article-title 44
###begin article-title 45
Synaptic plasticity and cell cycle activation in neurons are alternative effector pathways: the 'Dr. Jekyll and Mr. Hyde concept' of Alzheimer's disease or the yin and yang of neuroplasticity
###end article-title 45
###begin article-title 46
Differential involvement of 5-HT(1B/1D) and 5-HT6 receptors in cognitive and non-cognitive symptoms in Alzheimer's disease
###end article-title 46
###begin article-title 47
###xml 98 104 <span type="species:ncbi:9606">humans</span>
###xml 119 127 <span type="species:ncbi:9606">patients</span>
Neurotransmitters, peptides, and neural cell adhesion molecules in the cortices of normal elderly humans and Alzheimer patients: a comparison
###end article-title 47
###begin article-title 48
The cholinergic hypothesis of Alzheimer's disease: a review of progress
###end article-title 48
###begin article-title 49
The electrophysiology of prefrontal serotonin systems: therapeutic implications for mood and psychosis
###end article-title 49
###begin article-title 50
Serotonin in aging, late-life depression, and Alzheimer's disease: the emerging role of functional imaging
###end article-title 50
###begin article-title 51
Role of serotonin in the behavioral and psychological symptoms of dementia
###end article-title 51
###begin article-title 52
A review of central 5-HT receptors and their function
###end article-title 52
###begin article-title 53
Serotonin model of schizophrenia: emerging role of glutamate mechanisms
###end article-title 53
###begin article-title 54
The physiological role of 5-HT2A receptors in working memory
###end article-title 54
###begin article-title 55
###xml 78 83 <span type="species:ncbi:9606">human</span>
Changes in serotonin2A and GABA(A) receptors in schizophrenia: studies on the human dorsolateral prefrontal cortex
###end article-title 55
###begin article-title 56
Serotonin receptors: their key role in drugs to treat schizophrenia
###end article-title 56
###begin article-title 57
The therapeutic role of 5-HT(1A) and 5-HT(2A) receptors in depression
###end article-title 57
###begin article-title 58
Higher expression of serotonin 5-HT(2A) receptors in the postmortem brains of teenage suicide victims
###end article-title 58
###begin article-title 59
5-Hydroxytryptamine2A serotonin receptors in the primate cerebral cortex: possible site of action ofhallucinogenic and antipsychotic drugs in pyramidal cell apical dendrites
###end article-title 59
###begin article-title 60
Serotonin5-HT2a and 5-HT2c receptors stimulate amyloid precursor protein ectodomain secretion
###end article-title 60
###begin article-title 61
5-HT2A and 5-HT2C receptor polymorphisms and psychopathology in late onset Alzheimer's disease
###end article-title 61
###begin article-title 62
Association of the serotonin transporter and receptor gene polymorphisms in neuropsychiatric symptoms in Alzheimer disease
###end article-title 62
###begin article-title 63
Depression in Alzheimer's disease: the effect of serotonin receptor gene variation
###end article-title 63
###begin article-title 64
5-HT6 receptors as emerging targets for drug discovery
###end article-title 64
###begin article-title 65
Influence of the 5-HT6 receptor on acetylcholine release in the cortex: pharmacological characterization of 4-(2-bromo-6-pyrrolidin-1- ylpyridine-4-sulfonyl)phenylamine, a potent and selective 5-HT6 receptor antagonist
###end article-title 65
###begin article-title 66
Association of the HTR6 polymorphism C267T with late-onset Alzheimer's disease in Chinese
###end article-title 66
###begin article-title 67
Association analysis of HTR6 and HTR2A polymorphisms in sporadic Alzheimer's disease
###end article-title 67
###begin article-title 68
Serotonin brain circuits involved in major depression and suicide
###end article-title 68
###begin article-title 69
###xml 40 48 <span type="species:ncbi:9606">patients</span>
Presynaptic serotonergic dysfunction in patients with Alzheimer's disease
###end article-title 69
###begin article-title 70
Physiological antagonism between 5-hydroxytryptamine(2A) and group II metabotropic glutamate receptors in prefrontal cortex
###end article-title 70
###begin article-title 71
###xml 125 128 <span type="species:ncbi:10116">rat</span>
Adenosine preferentially suppresses serotonin2A receptor-enhanced excitatory postsynaptic currents in layer V neurons of the rat medial prefrontal cortex
###end article-title 71
###begin article-title 72
Serotonergic control ofprefrontal cortex
###end article-title 72
###begin article-title 73
Delusional thoughts and regional frontal/temporal cortex metabolism in Alzheimer's disease
###end article-title 73
###begin article-title 74
Regional cerebral metabolism in early Alzheimer's disease with clinically significant apathy or depression
###end article-title 74
###begin article-title 75
Brain perfusion correlates of the apathy inventory dimensionsof Alzheimer's disease
###end article-title 75
###begin article-title 76
Neuropathological stageing of Alzheimer-related changes
###end article-title 76
###begin article-title 77
Practical measures to simplify the Braak tangle staging method for routine pathological screening
###end article-title 77
###begin article-title 78
Nitric oxide synthase neurons in different areas of normal aged and Alzheimer's brains
###end article-title 78
###begin article-title 79
Activated astrocytesdisplay increased 5-HT2a receptor expression in pathological states
###end article-title 79
###begin article-title 80
Segregation of serotonin 5-HT2A and 5-HT3 receptors in inhibitory circuits of the primate cerebral cortex
###end article-title 80
###begin article-title 81
###xml 84 87 <span type="species:ncbi:10116">rat</span>
Serotonin 5-HT2A receptors are expressed on pyramidal cells and interneurons in the rat cortex
###end article-title 81
###begin article-title 82
###xml 110 113 <span type="species:ncbi:10116">rat</span>
Cellular and subcellular distribution of the serotonin 5-HT2A receptor in the central nervous system of adult rat
###end article-title 82
###begin article-title 83
5-HT6 receptor binding sites in schizophrenia and following antipsychotic drug administration: autoradiographic studies with 125I]SB-258585
###end article-title 83
###begin article-title 84
###xml 66 69 <span type="species:ncbi:10116">rat</span>
Localization of serotonin subtype 6 receptor messenger RNA in the rat brain by in situ hybridization histochemistry
###end article-title 84
###begin article-title 85
###xml 79 84 <span type="species:ncbi:10090">mouse</span>
###xml 130 133 <span type="species:ncbi:10116">rat</span>
###xml 138 143 <span type="species:ncbi:9606">human</span>
Differences in the central nervous system distribution and pharmacology of the mouse 5-hydroxytryptamine-6 receptor compared with rat and human receptors investigated by radioligand binding, site-directed mutagenesis, and molecular modeling
###end article-title 85
###begin article-title 86
Serotonin receptor changes in dementia of the Alzheimer type
###end article-title 86
###begin article-title 87
Circumscribed changes of the cerebral cortex in neuropsychiatric disorders of later life
###end article-title 87
###begin article-title 88
Loss of serotonin 5-HT2A receptors in the postmortem temporal cortex correlates with rate of cognitive decline in Alzheimer's disease
###end article-title 88
###begin article-title 89
Altered cortical serotonergic binding
###end article-title 89
###begin article-title 90
PET imaging of serotonin type 2A receptors in late-life neuropsychiatric disorders
###end article-title 90
###begin article-title 91
5 HT2 receptors in dementia of Alzheimer type: a quantitative autoradiographic study of frontal cortex and hippocampus
###end article-title 91
###begin article-title 92
Topographical distribution of neurochemical changes in Alzheimer's disease
###end article-title 92
###begin article-title 93
Presynaptic serotonergic markers in community-acquired cases of Alzheimer's disease: correlations with depression and neuroleptic medication
###end article-title 93
###begin article-title 94
Neuropathology of aminergic nuclei in Alzheimer's disease
###end article-title 94
###begin article-title 95
###xml 66 74 <span type="species:ncbi:9606">patients</span>
Immunocytochemical study of the dorsal and median raphe nuclei in patients with Alzheimer's disease prospectively assessed for behavioural changes
###end article-title 95
###begin article-title 96
Nucleus raphe dorsalis in dementia of the Alzheimer type: neurofibrillary changes and neuronal packing density
###end article-title 96
###begin article-title 97
###xml 123 131 <span type="species:ncbi:9606">patients</span>
Terminal dUTP nick end labeling (TUNEL) positive cells in the different regions of the brain in normal aging and Alzheimer patients
###end article-title 97
###begin article-title 98
###xml 54 62 <span type="species:ncbi:9606">patients</span>
Serotonergic pathology is not widespread in Alzheimer patients without prominent aggressive symptoms
###end article-title 98
###begin title 99
Figures and Tables
###end title 99
###begin p 100
###xml 4 7 4 7 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A </sub>
###xml 0 15 0 15 <bold xmlns:xlink="http://www.w3.org/1999/xlink">5-HT<sub>2A </sub>receptor</bold>
###xml 44 47 44 47 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A </sub>
###xml 123 130 <span type="species:ncbi:9606">patient</span>
###xml 319 326 <span type="species:ncbi:9606">patient</span>
5-HT2A receptor. Immunoreaction for the 5-HT2A receptor in the prefrontal cortex of a normal aging (a, c) and an Alzheimer patient (b, d), cresyl violet counterstain. Both large pyramidal cells (arrowheads) and small interneurons (arrows) are stained. Note the reduction in labeled cells in the cortex of the Alzheimer patient (b, d). a, b: x200; c, d; x400.
###end p 100
###begin p 101
###xml 0 16 0 16 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Cell densities. </bold>
###xml 41 44 41 44 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A </sub>
###xml 52 54 52 54 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6 </sub>
###xml 152 160 <span type="species:ncbi:9606">patients</span>
Cell densities. Numerical density of 5-HT2A and 5-HT6 receptor immunoreactive neurons in the prefrontal cortex of normal aging (n=7) and Alzheimer (AD) patients (n=6). Depicted are means +/- SEM. Significant differences (p </= 0.05) are marked by an asterisk (*)
###end p 101
###begin p 102
###xml 4 6 4 6 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6 </sub>
###xml 0 16 0 16 <bold xmlns:xlink="http://www.w3.org/1999/xlink">5-HT<sub>6 </sub>receptor. </bold>
###xml 20 22 20 22 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6 </sub>
###xml 117 125 <span type="species:ncbi:9606">patients</span>
###xml 360 367 <span type="species:ncbi:9606">patient</span>
###xml 447 454 <span type="species:ncbi:9606">patient</span>
5-HT6 receptor. 5-HT6 receptor immunoreactive cells in the prefrontal cortex of normal aging (a, c, d) and Alzheimer patients (b, e), cresyl violet counterstain. Label is observed in large pyramidal cells (arrowhead) and small interneurons (arrow). Note positive cells and dense immunoreactive fibers in the molecular layer (d). In the cortex of the Alzheimer patient (b, e), significantly fewer cells are labeled than in that of the normal aging patient (a, c, d). a, b: x200; c, d, e; x400.
###end p 102
###begin p 103
###xml 52 60 <span type="species:ncbi:9606">patients</span>
Profiles of Alzheimer (AD) and matched normal aging patients
###end p 103

